中华肝脏病杂志Pub Date : 2024-09-03DOI: 10.3760/cma.j.cn501113-20231225-00299
Q Q Zhang, Y Chen, Y X Chen, L Yang
{"title":"[Update on Tolvaptan for the Treatment of Refractory Ascites in Liver Cirrhosis].","authors":"Q Q Zhang, Y Chen, Y X Chen, L Yang","doi":"10.3760/cma.j.cn501113-20231225-00299","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231225-00299","url":null,"abstract":"<p><p>Ascites is the most prevalent complication of decompensated cirrhosis, and approximately 5%-10% of cirrhotic ascites will develop into refractory ascites (RA). With complicated pathogenesis, obscure treatment strategies and poor prognosis, it is still a challenge for physicians to manage RA properly. Tolvaptan (TLV) is a new type of non-peptide selective arginine vasopressin V2 receptor antagonist targeting at suppressing renal water reabsorption, promoting free water excretion and raising blood sodium levels, which provides a new option for the treatment of RA in liver cirrhosis. In this review, we summarized the mechanisms of TLV's effect and described its efficacy, safety and predictive factors of response in treating RA, intending to provide a supplement for clinical application of tolvaptan in the management of RA.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240321-00148
Z P Lin, X G Zou, X L Hu, D B Huang, Y Chen, X Q Li, J Zhang
{"title":"[A case of bronchobiliary fistula treated by percutaneous endobiliary fistula closure].","authors":"Z P Lin, X G Zou, X L Hu, D B Huang, Y Chen, X Q Li, J Zhang","doi":"10.3760/cma.j.cn501113-20240321-00148","DOIUrl":"10.3760/cma.j.cn501113-20240321-00148","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"767-768"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240118-00036
T T He, X Li, M Gong
{"title":"[A case report of immune checkpoint inhibitor-related adverse reactions predominantly manifests as tumor-type reactive cutaneous capillary endothelial hyperplasia].","authors":"T T He, X Li, M Gong","doi":"10.3760/cma.j.cn501113-20240118-00036","DOIUrl":"10.3760/cma.j.cn501113-20240118-00036","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"764-766"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20231030-00161
X Luo, S X Li, L Hai, S W Liu, X C Ding, X Y Liu, L N Ma
{"title":"[Exploring potential serum metabolite markers of intrahepatic cholestasis based on liquid chromatography-mass spectrometry metabolomics technology].","authors":"X Luo, S X Li, L Hai, S W Liu, X C Ding, X Y Liu, L N Ma","doi":"10.3760/cma.j.cn501113-20231030-00161","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231030-00161","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the blood differential metabolites of patients with intrahepatic cholestasis (IHC) by liquid chromatography-mass spectrometry metabolomics technology so as to find potential metabolic target. <b>Method:</b> Serum samples were collected from thirty patients with intrahepatic cholestasis and thirty healthy individuals after metabolomics analysis. The differential metabolites were initially screened based on the multiple differences and significance. KEGG enrichment analysis was performed on the differential metabolites to determine the candidate targets. The potential clinical application value of these characteristic metabolites was analyzed using the receiver operating characteristic curve. <b>Result:</b> A total of thirty patients with intrahepatic cholestasis and thirty healthy adults were included. The age difference between the two groups was not statistically significant (<i>P</i>>0.05). The clinical condition was consistent with the statistically significant differences in liver biochemical indicators, blood routine, coagulation, and inflammatory indicators between the two groups (<i>P</i><0.05). Furthermore, a blood metabolomics screening analysis revealed 99 differentially expressed metabolites associated with intrahepatic cholestasis. Of these, 15 showed statistically significant differences. Glucose, lipid, and energy metabolisms were the various primary types of differential metabolites involved. The receiver operating characteristic curve>0.9 included the following twelve kinds of metabolites: 1H-indole-3-carboxaldehyde, 6-hydroxy-1H-indole-3-acetamide, phenylalanyl tryptophan, 1-methylguanosine, 2-ethoxy-5-methylpyrazine, p-hydroxybenzaldehyde, 5-(2-chlorophenyl)-3,4-dihydro-2H-pyrrole, methylthioadenosine, alanylisoleucine, anabsinthin, N-acetyl-DL-histidine monohydrate, N-methylnicotinamide, and others. The fifteen metabolites that were previously identified and calculated according to the differential quantitative value of the metabolite corresponding ratio exhibited fold-changes in the upregulated and downregulated potential biomarkers (phenylalanine tryptophan, phenylalanine, 5'-methylthioadenosine, anabsinthin, and N-methylnicotinamide) in combination with the area under the receiver operating characteristic curve>0.9. <b>Conclusion:</b> Phenylalanyl tryptophan, phenylalanylalanine, 5'-methylthioadenosine, anabsinthin, and N-methylnicotinamide may serve as potential metabolic markers to distinguish patients with cholestasis from healthy controls. N-methylnicotinamide, among them, is of great importance as a potential marker.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"753-760"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240529-00273
D Chang, J Yang, Y B Li, X Y Zhou, S S Ju
{"title":"[Current status and new advancements in molecular imaging of liver cancer].","authors":"D Chang, J Yang, Y B Li, X Y Zhou, S S Ju","doi":"10.3760/cma.j.cn501113-20240529-00273","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240529-00273","url":null,"abstract":"<p><p>Early-stage diagnosis of liver cancer is challenging, with an overall poor prognosis. The tumor microenvironment of primary liver cancer is complex, exhibiting significant heterogeneity both interpersonally and intratumorally. Therefore, it is of paramount importance to dynamically analyze biological markers in the tumor microenvironment of primary liver cancer <i>in vivo</i>. In recent years, significant progress has been made in the imaging diagnosis and treatment of liver cancer with the development of molecular imaging. Molecular imaging techniques utilize specific nano-imaging probes to evaluate pathological changes of liver cancer at the molecular and cellular levels in real-time. These techniques enable precise imaging to reveal key molecular biomarkers involved in the occurrence and progression of liver cancer, exploring their associations with cancer progression and outcomes. This article focuses on molecular imaging, emphasizing the current research status and latest advancements in the field of liver cancer diagnosis and therapy using techniques such as CT, MRI, optical imaging, PET imaging, and multimodal imaging. It also identifies important future directions and significant challenges for further development.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"688-694"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240716-00326
{"title":"[Chinese practice guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus (version 2024)].","authors":"","doi":"10.3760/cma.j.cn501113-20240716-00326","DOIUrl":"10.3760/cma.j.cn501113-20240716-00326","url":null,"abstract":"<p><p>The Chinese Clinical Practice Guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus, developed by the Chinese Society of Infectious Diseases of the Chinese Medical Association in 2019, serves as a valuable reference for standardizing the process of preventing mother-to-child transmission in China. As new evidence emerges, it is crucial that timely and regular updates are made to the clinical practice guidelines so that to optimize guidance for clinical practice and research. To this end, the Infectious Disease Physician Branch of Chinese Medical Doctor Association and the Chinese Society of Infectious Diseases of Chinese Medical Association, in collaboration with multidisciplinary experts, have updated the guidelines based on the latest domestic and international research advancements and clinical practice, in order to provide guidance and reference for clinicians and maternal and child healthcare workers.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"702-711"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240528-00272
X M Li, Z Y Liu
{"title":"[Research progress of radiomics in hepatocellular carcinoma].","authors":"X M Li, Z Y Liu","doi":"10.3760/cma.j.cn501113-20240528-00272","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240528-00272","url":null,"abstract":"<p><p>Primary liver cancer is a common malignant digestive system tumor, with hepatocellular carcinoma being the most common pathological type. Radiomics significantly boosts the efficiency of predictions by accurately capturing the intrinsically heterogeneous features of tumors that are difficult to discern with the human eye in imaging images. This article outlines the background and concepts of radiomics, introduces its latest research progress in various aspects, such as diagnosis and differential diagnosis, prediction of pathological molecular subtypes, efficacy evaluation, and survival prediction, and further discusses its limitations and prospects in HCC.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"679-687"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240723-00339
{"title":"[Expert recommendations on hepatitis B vaccination in adults].","authors":"","doi":"10.3760/cma.j.cn501113-20240723-00339","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240723-00339","url":null,"abstract":"<p><p>In order to achieve the target of eliminating viral hepatitis as a public health threat by 2030 and to prioritize the role of hepatitis B vaccination in reducing new hepatitis B virus infections, the Chinese Preventive Medicine Association commissioned experts to develop the <i>Expert Recommendations on Hepatitis B Vaccination in Adults</i> to scientifically guide adult hepatitis B vaccination,build the herd immunity in population, and reduce the hepatitis B virus infection rate and incidence of hepatitis B.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"712-717"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20240529-00275
J Zhou, T W Chen, D J Guo
{"title":"[Research progress and prospects of the application of radiographic imaging in the precise diagnosis and treatment of hepatocellular carcinoma].","authors":"J Zhou, T W Chen, D J Guo","doi":"10.3760/cma.j.cn501113-20240529-00275","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240529-00275","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a highly heterogeneous kind of malignant tumor with a high recurrence rate and low five-year survival rate, which has become one of the major public health issues in China. Currently, HCC is the only solid tumor that can be solely diagnosed based on epidemiological history and typical imaging features without preoperative pathological confirmation. The paradigm for HCC imaging diagnosis has shifted in recent years from anatomy to function, from macroscopic to microscopic, and from diagnosis to prediction in the context of precision medicine, making it possible to study the microscopic processes such as HCC genes and their metabolic laws from the perspective of qualitative and quantitative imaging, thereby providing more accurate biological and imaging information for elucidating the occurrence, development, and clinical treatment decisions of HCC.This paper reviews the research progress of HCC imaging in recent years, demonstrating the rapid horizontal development and enormous potential of imaging in the vertical follow-up of HCC precision diagnosis and treatment. Simultaneously, it also puts forward the shortcomings of current HCC imaging research and looks forward to future development directions in order to be more accurately used in clinical decision support systems.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"673-678"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
中华肝脏病杂志Pub Date : 2024-08-20DOI: 10.3760/cma.j.cn501113-20231115-00195
Z M Jiang, M Liu, C Y Zhang, X Z Liu
{"title":"[Primary malignant hepatic mesothelioma: a case report and literature review].","authors":"Z M Jiang, M Liu, C Y Zhang, X Z Liu","doi":"10.3760/cma.j.cn501113-20231115-00195","DOIUrl":"10.3760/cma.j.cn501113-20231115-00195","url":null,"abstract":"","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"761-763"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}